Patent 8,574,613 (US) Scope, Claim Strength, and US Landscape

US Patent 8,574,613 claims a sustained-release drug delivery system built around a core reservoir plus a dimensionally stable, agent-impermeable inner tube and an agent-permeable outer layer that is not fully covering the inner tube. Release occurs through open ends of the inner tube, and the outer layer covers only selected portions, creating a diffusion-controlled pathway after implantation.

The claim set is broad on architecture (tube + reservoir + selective outer permeability + release from open ends), and broad on materials and agent class. Dependent claims then tighten specific topologies (ports, permeable/impermeable end members, where the outer layer covers) and release behavior (diffusion area stability).

What is claimed in plain structural terms?

What are the independent claim themes (composition of the device)?

The core architecture across claims 1, 15, and 16 is consistent:

Drug reservoir with a therapeutically effective amount of an agent.
Inner tube
- has first and second open ends
- covers at least a portion of the drug reservoir
- is impermeable to passage of the agent
- is dimensionally stable and can support its own weight
Outer layer
- is permeable to passage of the agent
- covers only a portion of the inner tube in claim 1
- the outer layer may cover open ends in the narrower variants (claim 14 and the injectable version claim 16)
Release mechanism on implantation
- agent releases through at least one open end (claim 1 and claim 16)
- specific directionality is built into some dependent/narrow claims (claim 15: release through the second open end only in the described configuration)

What variants expand or narrow the release pathway?

Three main variants appear:

Selective outer coverage with dual-ended options (claim 1)
- outer layer covers only a portion of inner tube
- release occurs through at least one open end
End-member control at the first open end (claims 3 to 5)
- impermeable or permeable members can be placed at the inner tube open ends
- creates additional control over whether diffusion can occur immediately at an open end
Outer layer coverage pattern (claims 14 and 16)
- claim 14: outer layer covers both open ends
- claim 16: “injectable” sustained release form where outer layer covers open ends but only a portion of reservoir/inner tube
Directional release configuration (claim 15)
- impermeable member at first open end
- outer layer covering only a portion of inner tube
- release through the second open end

Claim-by-claim scope analysis

Claim 1 is the anchor architecture

Claim 1 broadly covers the system as a sustained release device with:

Reservoir + impermeable inner tube (dimensionally stable; self-supporting; agent-impermeable)
Outer layer permeable to agent
Outer layer covers only a portion of the inner tube
After implantation, release through at least one open end

This is a strong “architecture” claim because it is not limited to a specific polymer class, specific agent, or specific port configuration.

Claim 2 adds inner-tube perforation

Claim 2 adds: inner tube includes at least one port or hole.
This shifts the claim from purely “end release” to allowing additional structural diffusion points.

Claims 3 to 5 add end-member constraints

Claim 3: impermeable member at first open end
Claim 4: permeable member at first open end
Claim 5: permeable member also at second open end (depends from claim 4)

These create enforceable narrower subsets where the open-end interface is engineered to be either permissive or blocking.

Claim 6 adds ports in the outer layer

Claim 6: outer layer includes at least one port or hole.
This provides an alternative route for diffusion depending on outer-layer permeability/holes.

Claims 7 and 8 lock in broad polymer material lists

Claim 7: inner tube formed from a long list of materials (many polymers and elastomers, including EVA, PVA, PVAc, PVDF, PTFE, nitriles, various chlorinated polymers, silicones, rubbery polymers).
Claim 8: outer layer is formed from similarly broad material list.

Impact:

These lists are wide enough that most conventional polymer implantable membrane/tube materials will map.
The material enumeration is long and reduces the chance of an easy “design-around by using a different polymer family,” as long as accused devices use one of the enumerated materials.
If an accused product uses a materially different polymer not on the list, claim coverage narrows to the extent a strict reading is required (depends on interpretation in prosecution, but text lists materials explicitly).

Claims 9 to 12 cover agent classes and examples

Claim 9: agent selected from a broad list spanning anesthetics, anti-cancer, anti-inflammatory, anti-viral, peptides/proteins, steroids/corticosteroids, carbonic anhydrase inhibitors, neuroprotectants, antibiotics, anti-allergens, decongestants, glaucoma agents, immunological modifiers, miotics/anti-cholinesterase, prodrugs.
Claim 10: further enumerates many specific agents (includes lidocaine, benzodiazepines like diazepam-type category not explicitly but “benzodiazepam,” multiple antivirals including acyclovir-like, oncology drugs including 5-FU and adriamycin, glaucoma drugs timolol/betaxolol/atenolol-like list, corticosteroids including hydrocortisone/dexamethasone variants, and many antibiotics).
Claim 11: agent is an anti-viral agent (from claim 10 + claim 9 family).
Claim 12: anti-viral narrowed to a subset: trisodium phosphomonoformate, trifluorothymidine, acyclovir, ganciclovir, DDI, DDC, AZT, idoxuridine (and salts).

From a landscape viewpoint, this means the patent has strong claim value in antiviral sustained release implant contexts, especially where the agent is among the enumerated set.

Claim 13 adds a quantitative dimensional stability criterion

Claim 13 requires that the inner tube is dimensionally stable such that:

diffusion area does not change more than 50% from what is expected based on the chemical potential gradient across the system.

This is a meaningful tightening. It turns “dimensionally stable” from a functional statement into a measurable performance constraint. Enforcement depends on how “expected based on chemical potential gradient” is determined in practice, but as written it adds an experimentally testable element.

Claim 14 sets outer layer coverage to include open ends

Claim 14: outer layer covers the first and second open ends.
This is narrower than claim 1’s “covers only a portion” because it requires full end coverage.

Claim 15 narrows to a directional two-part end-member architecture

Claim 15 is a system with:

drug reservoir
inner tube with first and second open ends; inner tube impermeable; self-supporting/ dimensionally stable
impermeable member at first open end
outer layer permeable covering only a portion of inner tube
release through the second open end

Compared to claim 1:

It blocks the first end via impermeable member.
It creates a directional release requirement (only second open end in the described configuration).

Claim 16 adds “injectable”

Claim 16: an injectable sustained release drug delivery system with:

reservoir + impermeable, dimensionally stable, self-supporting inner tube
outer layer permeable
outer layer covers first and second open ends
outer layer covers only a portion of reservoir and/or inner tube
upon implantation, release through at least one open end

This matters because “injectable” can distinguish the form factor from an implant inserted by trochar, though the mechanical details are not specified in your excerpt.

Claim 17 is a specific product-like tie to a corticosteroid

Claim 17: in accordance with claim 10, agent is fluocinolone acetonide.
This is the narrowest “agent example” and is often how patents capture a commercial product or known therapeutic target population.

Scope map: what the claims cover vs. where design-arounds likely occur

Where the claim scope is broad

The breadth is anchored in:

Device architecture (impermeable inner tube + permeable outer layer + open ends + selective outer coverage)
Agent selection (claim 9 and claim 10 enumerate a wide field)
Polymer material options (claim 7 and 8 lists dozens of materials for both inner and outer)

This combination makes claim 1 the primary coverage driver for most variations that still keep the “tube + selective permeable outer + end release” structure.

Where the claim scope narrows

Coverage narrows materially if any of these elements are missing:

No impermeable inner tube (agent crosses inner tube wall)
No dimensionally stable, self-supporting tube (functional element may become a factual dispute)
Outer layer is not “permeable to agent”
Outer layer covers the inner tube differently (claim 14 requires end coverage; claim 1 requires only partial coverage)
End release mechanism differs (e.g., release through sidewall diffusion only, or through a single non-open end pathway)
Agent is outside the enumerated list for claims 10 to 12 or if relying on claim 17 for fluocinolone acetonide
Inner tube lacks ports if enforcement relies on claim 2
End-member composition differs if enforcement relies on claims 3 to 5 or claim 15

Quantitative and functional hooks that may drive infringement analysis

What tests could be used against claim terms?

The claims provide hooks that are more than purely qualitative:

Permeability:
- outer layer must be “permeable to passage of the agent”
- inner tube must be “impermeable to passage of the agent”
Dimensional stability:
- claim 13 requires a diffusion area change not exceeding 50% vs expectation based on chemical potential gradient
Geometry and coverage:
- outer layer covers “only a portion” (claim 1, claim 15)
- outer layer covers both open ends (claim 14, claim 16)
Open-end release:
- release through at least one open end (claim 1 and 16)
- release through the second open end when the first open end is blocked (claim 15)

These terms can be mapped into mechanical and transport characterization, but enforcement strategy will depend on the accused product’s structure.

US patent landscape: how this claim set typically sits in the field

How to position US 8,574,613 in the “device architecture” landscape

In US sustained release implant/device patents, claim sets usually compete on:

reservoir membrane/tube structure
rate control via diffusion barrier
end-side release gating
polymer selection and permeability control
injectability/form factor

US 8,574,613 is distinct because it combines:

an impermeable, self-supporting tube covering a portion of reservoir
a permeable outer layer with partial coverage
release through tube open ends, not through a continuously covered membrane surface

That structure tends to align the patent with other patents that claim “end release” or “selective permeability” controlled release systems for local drug delivery.

Most likely infringement focus

For most product designs that use a similar two-layer configuration, enforcement typically starts at claim 1, then “falls through” to narrower claims depending on the product’s specific end-member features, ports, outer coverage, and polymer materials.

For antiviral or fluocinolone acetonide products, enforcement can also target:

claim 11/12 (anti-viral)
claim 17 (fluocinolone acetonide)

Strength, weakness, and practical coverage summary

How strong is claim 1 relative to the dependents?

Claim 1 is the broadest and likely the best anchor for:

broad product configurations that keep the inner impermeable tube and permeable outer partial coverage
agents that fall under claim 9/10 (even if the device is identical, claim 1 as written still requires an agent; dependent claim 9/10 matter when agent is outside the enumerated sets)

Dependents add specificity and typically narrow scope; they are valuable when claim 1 is threatened by prior art or when a particular product feature is undeniable.

Where prior-art invalidity risk tends to concentrate

Invalidity often attacks:

“tube-impermeable / outer permeable” combinations
open-end release gating
polymer-permeability selectivity
known “leakproof inner liner + permeable outer membrane” release systems

Without prosecution history or citations, the only firm points from the text are that the patent includes very broad enumerations of materials and agents; that breadth can help claim coverage but can also make it harder to distinguish over prior art that uses the same conceptual architecture with different choices.

Claim chart style mapping (device elements to claim language)

Device element	Claim language requirement	Coverage implication
Reservoir	“drug reservoir comprising a therapeutically effective amount of said agent”	Core element; missing reservoir breaks coverage
Inner tube	inner tube with first and second open ends covering at least portion of reservoir	Establishes tube geometry and partial coverage
Inner tube permeability	inner tube is “impermeable to passage of the agent”	Requires a real barrier layer
Inner tube stability	“dimensionally stable” and “capable of supporting its own weight”	Adds mechanical/functional limitation
Outer layer permeability	“outer layer, permeable to passage of said agent”	Outer layer must allow diffusion
Outer layer coverage	covers “only a portion of said inner tube” (claim 1); varies in claim 14/16; “only a portion” in claim 15	Coverage pattern is a core differentiator
Release pathway	release through “at least one open end” (claim 1/16); through “second open end” in claim 15	End gating is central
Ports/holes	inner tube (claim 2) and/or outer layer (claim 6) include ports	Adds architectural specificity
End members	impermeable/permeable members at open ends (claims 3 to 5, claim 15)	Requires engineered end interfaces
Polymer materials	inner tube (claim 7) and outer layer (claim 8) from long enumerations	Captures many common polymer candidates; excludes non-listed if strict reading applies
Quantitative stability	diffusion area change not more than 50% (claim 13)	Performance test driver; narrows risk of functional-only readings
Agent constraints	agent class list (claim 9), specific agents (claim 10), anti-viral subset (claim 12), fluocinolone acetonide (claim 17)	Enables targeted enforcement for specific drug programs

Key Takeaways

US 8,574,613 claims a two-stage release architecture: an impermeable inner tube that is self-supporting and dimensionally stable plus a permeable outer layer with selective coverage, where drug releases through the inner tube open ends after implantation.
Claim 1 is the principal breadth driver; claims 3-6, 13-16 add practical constraints on end gating, porting, quantitative stability, outer coverage pattern, and injectability.
Agent and polymer coverage are broadly enumerated in claims 7-12 and 17, enabling claim alignment with many polymer choices and a wide list of drug agents, including antivirals and fluocinolone acetonide.
Enforcement and invalidity analysis will hinge on physical structure: impermeable inner barrier, partial permeable outer coverage, open-end release pathway, and (if asserted) quantitative diffusion-area stability.

FAQs

1) Which claim should be treated as the main infringement anchor?

Claim 1. It defines the overall device architecture (impermeable inner tube, permeable outer layer with partial coverage, and end release).

2) What feature most strongly differentiates this patent from “full-surface membrane” diffusion systems?

The outer layer covers only a portion of the inner tube in claim 1, and release occurs through open ends (not solely through a uniformly permeable surface).

3) Does the patent require that both ends release the drug?

No. Claim 1 allows release through at least one open end. Claim 15 is narrower and describes release through the second open end while the first open end is blocked.

4) What is the narrowest agent-specific claim in your excerpt?

Claim 17, which limits the agent to fluocinolone acetonide.

5) What claim introduces a quantitative performance threshold?

Claim 13, which limits diffusion area change to no more than 50% relative to an expected baseline based on chemical potential gradient.

References

[1] United States Patent 8,574,613, “Sustained release drug delivery system” (claims excerpt provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2233112	⤷ Start Trial	122014000063	Germany	⤷ Start Trial
European Patent Office	2233112	⤷ Start Trial	132014902285293	Italy	⤷ Start Trial
Argentina	028372	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,574,613